CellaVision AB (CLVSF)
OTHER OTC:CLVSF
CLVSF Stock Chart & Stats
$16.76
$0.00(0.00%)
At close: 4:00 PM EST
$16.76
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$12.25 - $20.69
Previous CloseN/A
Volume785.00
Average Volume (3M)133.00
Market Cap
$312.89M
Enterprise Value$2.67B
Total Cash (Recent Filing)$230.22M
Total Debt (Recent Filing)$22.43M
Price to Earnings (P/E)22.4
Beta0.65
Next Earnings
Jul 17, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend Yield1.37%
Share Statistics
EPS (TTM)5.62
Shares Outstanding23,851,547
10 Day Avg. Volume0
30 Day Avg. Volume133
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market Cap8.53
Enterprise Value/Revenue3.65
Enterprise Value/Gross Profit5.37
Enterprise Value/Ebitda13.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.76
Revenue Forecast (FY)$87.14M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and sizeable equity provide durable financial flexibility. This supports sustained R&D, distributor support and M&A optionality during cycles, reducing refinancing risk and enabling long-term investment in product development and global commercial expansion.
High And Stable MarginsPersistent high gross and net margins indicate structural product differentiation and pricing power in digital cell morphology. Durable margin structure supports reinvestment and profitability even with moderate revenue fluctuations, underpinning long-term cash generation.
Strong Operating Cash GenerationOperating cash significantly above reported earnings signals real cash profitability and working capital discipline. This enhances capability to fund maintenance capex, services, and recurring revenue investments without relying on external financing, supporting durable operations.
Bears Say
Recent Revenue DeclineA falling TTM revenue trend cuts into the growth runway for installed-base expansion and related recurring revenue. If sustained, it can reduce economies of scale, pressure margins and slow software/service attachment growth that support long-term revenue predictability.
Weakened Free Cash Flow ConversionA sharp drop in FCF conversion signals higher capex, working-capital strain or timing effects that reduce distributable cash. Lower conversion constrains dividend durability, share buybacks and reinvestment capacity, increasing sensitivity to revenue shocks over the medium term.
Negative Recent Growth MetricsDeclining organic revenue and EPS growth reflect near-term demand or margin pressure that could persist. Slowing fundamental growth raises the bar for operational leverage and makes long-term targets harder to achieve without stepped-up commercial or product initiatives.
CellaVision AB News
CLVSF FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was $12.25 and its highest was $20.69 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is $312.89M.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Jul 17, 2026 which is in 41 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Apr 24, 2026. The company reported $0.099 earnings per share for the quarter, missing the consensus estimate of $0.167 by -$0.067.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB pays a Annually dividend of $0.263 which represents an annual dividend yield of 1.37%. See more information on CellaVision AB dividends here
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 0.15.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of $0.099 in its last earnings report, missing expectations of $0.167. Following the earnings report the stock price went down -18.439%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in CLVSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
CLVSF Company Deck
CLVSF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: solid revenue and organic growth, a strong EBITDA margin above target, record Americas performance, important strategic progress (bone marrow CE Mark, software validation, DI-60 throughput improvements), a healthy cash position and a proposed dividend increase. Offsetting factors include a weak APAC quarter driven by comparables and tender timing, softness in reagents/software mix that pressured Q4 gross margin, FX headwinds, and near-term uncertainty on revenue ramp from new product launches (bone marrow and U.S. methanol-free reagents). Overall these negatives appear manageable against the company’s clear commercial momentum and strategic milestones.View all CLVSF earnings summariesTechnical Analysis
BICO Group AB Class B
―
Senzime AB
―
Xvivo Perfusion AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Ownership Overview
―
Insiders
1.11% Mutual Funds
<0.01% Other Institutional Investors
98.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---